271 related articles for article (PubMed ID: 33685036)
1. The Behavioral Effects of Combination Therapy of Memantine and Acetylcholinesterase Inhibitors Compared with Acetylcholinesterase Inhibitors Alone in Patients with Moderate Alzheimer's Dementia: A Double-Blind Randomized Placebo-Controlled Trial.
Youn H; Lee KJ; Kim SG; Cho SJ; Kim WJ; Lee WJ; Hwang JY; Han C; Shin C; Jung HY
Psychiatry Investig; 2021 Mar; 18(3):233-240. PubMed ID: 33685036
[TBL] [Abstract][Full Text] [Related]
2. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
Porsteinsson AP; Grossberg GT; Mintzer J; Olin JT;
Curr Alzheimer Res; 2008 Feb; 5(1):83-9. PubMed ID: 18288936
[TBL] [Abstract][Full Text] [Related]
3. Memantine and Acetylcholinesterase Inhibitor Use in Alzheimer's Disease Clinical Trials: Potential for Confounding by Indication.
Huisa BN; Thomas RG; Jin S; Oltersdorf T; Taylor C; Feldman HH
J Alzheimers Dis; 2019; 67(2):707-713. PubMed ID: 30636733
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
Cumbo E; Ligori LD
J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
[TBL] [Abstract][Full Text] [Related]
5. The Effect of Memantine on Cognitive Function and Behavioral and Psychological Symptoms in Mild-to-Moderate Alzheimer's Disease Patients.
Zhang N; Wei C; Du H; Shi FD; Cheng Y
Dement Geriatr Cogn Disord; 2015; 40(1-2):85-93. PubMed ID: 26066622
[TBL] [Abstract][Full Text] [Related]
6. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
[TBL] [Abstract][Full Text] [Related]
7. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B
Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967
[TBL] [Abstract][Full Text] [Related]
8. Effect of memantine combined with citalopram on cognition of BPSD and moderate Alzheimer's disease: A clinical trial.
Zhou T; Wang J; Xin C; Kong L; Wang C
Exp Ther Med; 2019 Mar; 17(3):1625-1630. PubMed ID: 30783429
[TBL] [Abstract][Full Text] [Related]
9. Time to Treatment Initiation in People With Alzheimer Disease: A Meta-Analysis of Randomized Controlled Trials.
Tsoi KK; Hirai HW; Chan JY; Kwok TC
J Am Med Dir Assoc; 2016 Jan; 17(1):24-30. PubMed ID: 26392193
[TBL] [Abstract][Full Text] [Related]
10. Memantine in behavioral variant frontotemporal dementia: negative results.
Vercelletto M; Boutoleau-Bretonnière C; Volteau C; Puel M; Auriacombe S; Sarazin M; Michel BF; Couratier P; Thomas-Antérion C; Verpillat P; Gabelle A; Golfier V; Cerato E; Lacomblez L;
J Alzheimers Dis; 2011; 23(4):749-59. PubMed ID: 21157021
[TBL] [Abstract][Full Text] [Related]
11. Early intervention and adding effective doses of EGb761 like
Özge A; Ghouri R; Öksüz N; Taşdelen B
Front Neurol; 2023; 14():1240655. PubMed ID: 38156089
[TBL] [Abstract][Full Text] [Related]
12. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.
Peskind ER; Potkin SG; Pomara N; Ott BR; Graham SM; Olin JT; McDonald S
Am J Geriatr Psychiatry; 2006 Aug; 14(8):704-15. PubMed ID: 16861375
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of memantine on neuropsychiatric symptoms associated with the severity of behavioral variant frontotemporal dementia: A six-month, open-label, self-controlled clinical trial.
Li P; Quan W; Zhou YY; Wang Y; Zhang HH; Liu S
Exp Ther Med; 2016 Jul; 12(1):492-498. PubMed ID: 27347084
[TBL] [Abstract][Full Text] [Related]
14. Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: the MEMAGE study.
Gareri P; Putignano D; Castagna A; Cotroneo AM; De Palo G; Fabbo A; Forgione L; Giacummo A; Lacava R; Marino S; Simone M; Zurlo A; Putignano S
J Alzheimers Dis; 2014; 41(2):633-40. PubMed ID: 24643135
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
Orgogozo JM; Rigaud AS; Stöffler A; Möbius HJ; Forette F
Stroke; 2002 Jul; 33(7):1834-9. PubMed ID: 12105362
[TBL] [Abstract][Full Text] [Related]
16. A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD).
Ballard C; Thomas A; Gerry S; Yu LM; Aarsland D; Merritt C; Corbett A; Davison C; Sharma N; Khan Z; Creese B; Loughlin P; Bannister C; Burns A; Win SN; Walker Z;
J Am Med Dir Assoc; 2015 Apr; 16(4):316-22. PubMed ID: 25523285
[TBL] [Abstract][Full Text] [Related]
17. Association between antidementia medication use and mortality in people diagnosed with dementia with Lewy bodies in the UK: A retrospective cohort study.
Chen S; Price AC; Cardinal RN; Moylett S; Kershenbaum AD; Fitzgerald J; Mueller C; Stewart R; O'Brien JT
PLoS Med; 2022 Dec; 19(12):e1004124. PubMed ID: 36472984
[TBL] [Abstract][Full Text] [Related]
18. Trends in the Prescription and Long-Term Utilization of Antidementia Drugs Among Patients with Alzheimer's Disease in Spain: A Cohort Study Using the Registry of Dementias of Girona.
Calvó-Perxas L; Turró-Garriga O; Vilalta-Franch J; Lozano-Gallego M; de Eugenio R; Márquez F; Carmona O; Gich J; Manzano A; Viñas M; Roig AM; Garre-Olmo J;
Drugs Aging; 2017 Apr; 34(4):303-310. PubMed ID: 28258538
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
